S1213
Clinical - Urology
ESTRO 2026
3 Radiation Oncology, University Hospital San Francisco de Asís, GenesisCare, Madrid, Spain. 4 Radiation Oncology, Blua Sanitas Valdebebas Hospital, Madrid, Spain. 5 Radiation Oncology, Santa Bárbara Hospital, Soria, Spain. 6 Radiation Oncology, National Cancer Institute, Ciudad de México, Mexico. 7 Radiation Oncology, Centro de Protonterapia Quirónsalud, Madrid, Spain. 8 Radiation Oncology, Centro Médico ABC, Ciudad de México, Mexico. 9 Radiation Oncology, Ramón y Cajal University Hospital, Madrid, Spain. 10 Radiation Oncology, Clínico San Carlos University Hospital, Madrid, Spain. 11 Radiation Oncology, GenesisCare Córdoba, Córdoba, Spain. 12 Radiation Oncology, GenesisCare Sevilla, Madrid, Spain. 13 Radiation Oncology, Miguel Servet University Hospital, Madrid, Spain. 14 Radiation Oncology, Fundación Jiménez Díaz University Hospital, Madrid, Spain. 15 Radiation Oncology, La Paz University Hospital, Madrid, Spain. 16 National Director, GenesisCare Spain, Madrid, Spain. 17 Department of Medicine, School of Medicine, Health and Sport, European University of Madrid, Madrid, Spain
Among 369 patients (median age 76 years; 85.1% male), CLR was achieved in 63.7%. Disease progression occurred in 28.8% (10.1% local, 10.7% systemic, 8.7% combined), and 9.7% required salvage cystectomy. At a median follow-up of 31 months, median overall and cancer-specific survival were 43 and 77 months, respectively.In multivariable analysis, weekly portal imaging independently correlated with lower CLR rates (OR 0.35; 95% CI 0.20–0.60; p < 0.001), whereas 5- fluorouracil–based chemoradiotherapy was associated with higher CLR probability (OR 4.9; 95% CI 1.1–22.1; p = 0.038). Use of volumetric modulated arc therapy (VMAT) showed a favorable, although not statistically significant, trend toward improved outcomes. Conclusion: In this large multicenter Spanish cohort, TMT achieved durable bladder preservation and survival outcomes comparable to international benchmarks, reinforcing its role as a standard alternative to RC for selected MIBC patients. Technical parameters—particularly image-guidance quality and chemotherapy regimen— proved critical for achieving optimal local control. These results highlight the value of collaborative, harmonized approaches to optimize bladder- preservation strategies across Europe. Keywords: bladder-preservation, bladder cancer, trimodality Digital Poster 2107 Tolerability and Early Outcomes of Post- Prostatectomy MR-Guided Adaptive SBRT: Results from a Prospective Trial Abrahams Ocanto 1,2 , Macarena Teja 1,2 , María González 1,2 , Castalia Fernández 3,2 , Lisselott Torres 3,2 , Gloria Guardia 3,2 , Daniela Gonsalves 3,2 , Gloria Sánchez 4 , Álvaro Gaona 5 , Jasuani Bravo 6 , Isabel Garrido 7 , Tomás González 8 , Fernando López- Campos 2,9 , Miren Gaztañaga 2,10 , Jon Andreescu 11 , José A Gónzalez Ferreira 12 , Claudia Colom 13 , Leticia Del Campo 14 , Luis Glaría 1,15 , Felipe Couñago 16,17 1 Radiation Oncology, San Francisco de Asís University Hospital, Madrid, Spain. 2 Radiation Oncology, Vithas La Milagrosa University Hospital, Madrid, Spain.
Made with FlippingBook - Share PDF online